Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Non-Current Debt (2019 - 2025)

Puma Biotechnology's Non-Current Debt history spans 7 years, with the latest figure at $10.9 million for Q2 2025.

  • For Q2 2025, Non-Current Debt fell 75.15% year-over-year to $10.9 million; the TTM value through Jun 2025 reached $10.9 million, down 75.15%, while the annual FY2024 figure was $21.7 million, 66.92% down from the prior year.
  • Non-Current Debt reached $10.9 million in Q2 2025 per PBYI's latest filing, up from $10.6 million in the prior quarter.
  • In the past five years, Non-Current Debt ranged from a high of $98.6 million in Q1 2023 to a low of $10.6 million in Q1 2025.
  • Average Non-Current Debt over 5 years is $68.5 million, with a median of $76.5 million recorded in 2021.
  • Peak YoY movement for Non-Current Debt: surged 42.17% in 2022, then tumbled 80.53% in 2025.
  • A 5-year view of Non-Current Debt shows it stood at $97.1 million in 2021, then increased by 1.25% to $98.3 million in 2022, then tumbled by 33.21% to $65.7 million in 2023, then tumbled by 66.92% to $21.7 million in 2024, then tumbled by 49.96% to $10.9 million in 2025.
  • Per Business Quant, the three most recent readings for PBYI's Non-Current Debt are $10.9 million (Q2 2025), $10.6 million (Q1 2025), and $21.7 million (Q4 2024).